Comparison of Day and Night Closed-loop With Faster-acting Insulin Aspart With Insulin Aspart (AP-MFT-01)

• ClinicalTrials.gov Identifier: NCT03579615
• Recruitment Status: Recruiting
• First Posted: July 6, 2018
• Last Update Posted: December 7, 2021
• Sponsor: Manchester University NHS Foundation Trust
• Collaborator: Novo Nordisk A/S
• Information provided by (Responsible Party): Manchester University NHS Foundation Trust

Study Description

Brief Summary:

The main objective of the study is to determine whether automated closed-loop using faster-acting insulin aspart will improve glucose control and reduce the burden of hypoglycaemia over a 23-hour period compared to insulin aspart under conditions mimicking under-estimation of meal carbohydrate content or missed meal bolus. Faster-acting insulin aspart (FIASP) is a novel formulation of insulin aspart in which two additional excipients (L-arginine and Niacinamide) have been added, resulting in accelerated initial absorption and more than double the glucose lowering effect in the first 30 minutes after subcutaneous administration using insulin pump. To date, no closed-loop study has been performed to evaluate the benefit of faster-acting aspart over insulin aspart during closed-loop system use.

Condition or disease	Intervention/treatment	Phase
Diabetes Mellitus, Type 1	Device: FIASP + closed loop device; Device: Insulin aspart (standard of care insulin) + closed loop device	Not Applicable

Detailed Description:

This is an open-label, single-centre, two-period, randomised, cross over study. The study involves a screening visit to assess participant eligibility and two 24 hour in-patient stays at the clinical research facility during which day and night glucose levels will be controlled by the closed-loop system with either faster-acting insulin aspart or insulin aspart.

Up to 22 adults with type 1 diabetes and treated with continuous subcutaneous insulin infusion will be recruited, aiming for 16 completed participants. Recruitment will take place at Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester, UK. Participants will attend the Manchester Clinical Research Facility (MCRF), Manchester, on two occasions. In random order, they will undergo two closed-loop study days using either faster-acting insulin aspart or insulin aspart. During the study days, the closed-loop control algorithm will automatically modulate d insulin infusion rate based on real-time subcutaneous glucose sensor measurements. Participants will receive standardised meals with half usual meal bolus for the evening meal and no meal bolus for lunch time meal during each study day.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 22 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Intervention Model Description: An open-label, single-centre, randomised, two-period, cross-over study
• Masking: None (Open Label)
• Masking Description: FIASP vs standard of care insulin
• Primary Purpose: Other
• Official Title: An Open-label, Single-centre, Randomised, Two-period, Cross-over Study to Assess the Efficacy and Safety of Day and Night Automated Closed-loop Glucose Control for 24 Hours in Adults With Type 1 Diabetes Comparing Faster-acting Insulin Aspart With Insulin Aspart
• Actual Study Start Date: December 23, 2020
• Estimated Primary Completion Date: July 1, 2022
• Estimated Study Completion Date: July 1, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: FIASP + closed loop device; Subjects randomised to FIASP and closed loop device will be invited to have blood samples taken at baseline, CGM training, competency assessment, and optimisation of treatment. This is followed by inpatient stay where patients will be using FIASP + closed loop intervention for 24 hours. Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).	Device: FIASP + closed loop device; Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
Active Comparator: Insulin aspart (standard of care insulin) + closed loop device; Subjects randomised to insulin aspart (standard of care insulin) and closed loop device will be invited to have blood samples taken at baseline, CGM training, competency assessment, and optimisation of treatment. This is followed by inpatient stay where patients will be using insulin aspart (standard of care insulin) + closed loop intervention for 24 hours.Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).	Device: Insulin aspart (standard of care insulin) + closed loop device; Participants will be advised to maintain their usual insulin 24 hours prior to admission.

Outcome Measures

Primary Outcome Measures :

1. Time spent in the target glucose range [ Time Frame: 23 hours ]
   Time spent in the target glucose range between 3.9 to 10.0 mmol/l (70 to 180mg/dl) based on sensor glucose levels between the hours of 19:00 on day 1 and 18:00 hours on day 2 of the inpatient stay.

Secondary Outcome Measures :

1. Time spent in the target glucose range within 4 hours of each meal [ Time Frame: 4 hours ]
   Time spent in the target glucose range between 3.9 to 10.0 mmol/l (70 to 180mg/dl) based on sensor glucose levels during the first 4 hours following each meal
2. Incremental area under the curve of sensor glucose level within 4 hours of each meal [ Time Frame: 4 hours ]
   Incremental area under the curve of sensor glucose level during the first 4 hours after each meal
3. Time spent below target glucose [ Time Frame: 23 hours ]
   Time spent below target glucose (<3.9mmol/l) (<70mg/dl)
4. Time spent above target glucose [ Time Frame: 23 hours ]
   Time spent above target glucose (10.0 mmol/l) (180 mg/dl)
5. Average, coefficient of variation and standard deviation glucose levels [ Time Frame: 23 hours ]
   Average, coefficient of variation and standard deviation glucose levels
6. The time with sensor glucose levels < 3.5 mmol/l (63 mg/dl) [ Time Frame: 23 hours ]
   The time with sensor glucose levels < 3.5 mmol/l (63 mg/dl)
7. The time with sensor glucose levels <3.0 (54mg/dl) [ Time Frame: 23 hours ]
   The time with sensor glucose levels <3.0 (54mg/dl)
8. The time with sensor glucose levels <2.8 mmol/l (50 mg/dl) [ Time Frame: 23 hours ]
   The time with sensor glucose levels <2.8 mmol/l (50 mg/dl)
9. The time with sensor glucose levels in the significant hyperglycaemia [ Time Frame: 23 hours ]
   The time with sensor glucose levels in the significant hyperglycaemia (glucose levels > 16.7 mmol/l) (300mg/dl)
10. Total, basal and bolus insulin dose [ Time Frame: 23 hours ]
    Total, basal and bolus insulin dose
11. AUC of glucose below 3.0mmol/l (54mg/dl) [ Time Frame: 23 hours ]
    AUC of glucose below 3.0mmol/l (54mg/dl)

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. The subject is 18 years and older
2. The subject has type 1 diabetes, as defined by WHO for at least 1 year or is confirmed C-peptide negative
3. The subject will have been an insulin pump user for at least 3 months
4. The subject is treated with any of the rapid acting insulin analogues
5. The subject is willing to adhere to study procedures
6. HbA1c ≥ 7.0% (53 mmol/mol) and ≤ 10 % (86mmol/mol) based on analysis from local laboratory or equivalent within 3 months prior to enrolment
7. The subject is literate in English

Exclusion Criteria:

• 1. Non-type 1 diabetes mellitus including those secondary to chronic disease 2. Any other physical or psychological disease likely to interfere with the normal conduct of the study 3. Untreated celiac disease or hypothyroidism 4. Current treatment with drugs known to interfere with glucose metabolism, e.g. systemic corticosteroids, Metformin, SGLT2 inhibitors, non-selective beta-blockers and MAO inhibitors etc.

  5. Known or suspected allergy against insulin 6. Subjects with clinical significant nephropathy, neuropathy or proliferative retinopathy as judged by the investigator 7. Total daily insulin dose > 2 U/kg/day 8. Total daily insulin dose < 10 U/day 9. Pregnancy, planned pregnancy, or breast feeding

Contacts and Locations

Contacts

Contact: Stephanie Yau, MSc; 0161 276 6706; stephanie.yau@mft.nhs.uk

Contact: Lalantha Leelarathna, Dr; 0161 276 6706; lalantha.leelarathna@mft.nhs.uk

Locations

United Kingdom

Manchester University Hospitals NHS Foundation Trust; Recruiting

Manchester, United Kingdom, M13 WL

Contact: Lalantha Leelarathna

Sponsors and Collaborators

Manchester University NHS Foundation Trust

Novo Nordisk A/S

More Information

• Responsible Party: Manchester University NHS Foundation Trust
• ClinicalTrials.gov Identifier: NCT03579615
• Other Study ID Numbers: R04695
• First Posted: July 6, 2018
• Last Update Posted: December 7, 2021
• Last Verified: December 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Diabetes Mellitus, Type 1; Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases; Insulin; Insulin Aspart; Hypoglycemic Agents; Physiological Effects of Drugs